BIOTECHNOLOGY VALUE FUND II LP's Net Worth
$0
Who is BIOTECHNOLOGY VALUE FUND II LP?
BIOTECHNOLOGY VALUE FUND II LP does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Allakos Inc., Rain Therapeutics Inc., ARENA PHARMACEUTICALS INC, IMMUNE DESIGN CORP., Oncothyreon Inc., ORTHOLOGIC CORP, ChemoCentryx, Inc., DYNAVAX TECHNOLOGIES CORP, REPLIGEN CORP, KENT INTERNATIONAL HOLDINGS INC, NEUROCRINE BIOSCIENCES INC, XOMA Corp, LIGAND PHARMACEUTICALS INC, RIGEL PHARMACEUTICALS INC, Xenon Pharmaceuticals Inc., Cullinan Oncology, Inc., Merus N.V., Nivalis Therapeutics, Inc., Repare Therapeutics Inc., PIERIS PHARMACEUTICALS, INC., Verastem, Inc., Syndax Pharmaceuticals Inc, CTI BIOPHARMA CORP, IDEAYA Biosciences, Inc., CYTOKINETICS INC, Kymera Therapeutics, Inc., CURIS INC, Calithera Biosciences, Inc., CONCERT PHARMACEUTICALS, INC., PALATIN TECHNOLOGIES INC, MEDICINOVA INC, TARGACEPT INC, CytomX Therapeutics, Inc., MoonLake Immunotherapeutics, GLYCOMIMETICS INC, Principia Biopharma Inc., INFINITY PHARMACEUTICALS, INC., Eledon Pharmaceuticals, Inc., Olema Pharmaceuticals, Inc., Regulus Therapeutics Inc., ADVANCED MAGNETICS INC, ESSA Pharma Inc., 4D Molecular Therapeutics, Inc., NPS PHARMACEUTICALS INC, ICAGEN INC, ADOLOR CORP, Third Harmonic Bio, Inc., ZONAGEN INC, COMBINATORX, INC, Regado Biosciences Inc, SUPERGEN INC, FIVE PRIME THERAPEUTICS, INC., Structure Therapeutics Inc., ARRAY BIOPHARMA INC, ARQULE INC, AEOLUS PHARMACEUTICALS, INC., INHIBITEX, INC., NEUROBIOLOGICAL TECHNOLOGIES INC /CA/, enGene Holdings Inc., Celera CORP, FACET BIOTECH CORP, PHARMACOPEIA INC, AVIGEN INC \DE, SGX PHARMACEUTICALS, INC., VIACELL INC, NEUROGEN CORP, POINT Biopharma Global Inc., GENAERA CORP, AEROGEN INC, CORVAS INTERNATIONAL INC, BIOCRYST PHARMACEUTICALS INC, and APPLIED MOLECULAR EVOLUTION INC.
SEC CIK
BIOTECHNOLOGY VALUE FUND II LP's CIK is 0001102444
Past Insider Trading and Trends
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Allakos Inc. (ALLK) Snapshot price: $0.648
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Rain Therapeutics Inc. (RAIN) No price found
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -8.58M |
—
|
—
|
0
|
Jan 25 - Jan 26
| |||
Form 4
| +47.80% | 1.71M |
$5.83 | $9,971,387.14 | 5.29M |
Nov 8
| |||
Form 4
| +20.43% | 557.73K |
$12.00 | $6,692,637.85 | 3.29M |
Jan 6 - Jan 7
| |||
Form 4
| +0.41% | 11.03K |
$13.94 | $153,828.71 | 2.73M |
Sep 21
| |||
Form 4
| +16.86% | 392.27K |
$16.49 | $6,468,515.81 | 2.72M |
Sep 13
| |||
Form 4
| +33.73% | 587K |
$15.47 | $9,078,692.10 | 2.33M |
Jul 1 - Jul 6
| |||
Form 4
| +7.63% | 123.35K |
$15.94 | $1,966,334.17 | 1.74M |
May 21 - May 24
| |||
Form 4
| +14.80% | 208.47K |
$16.59 | $3,457,720.14 | 1.62M |
May 18 - May 19
| |||
Form 4
| +4.30% | 58K |
$14.26 | $827,167.00 | 1.41M |
May 13
| |||
Form 4/A
| +522.18% | 1.13M |
$16.86 | $19,103,379.78 | 1.35M |
Apr 23 - Apr 26
| |||
Form 4
|
∞
| 4.93M |
$16.86 |
—
| 4.93M |
Apr 23 - Apr 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ARENA PHARMACEUTICALS INC No price found
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -12.32% | -828.09K |
$5.10 | -$4,219,175.99 | 5.89M |
Jul 7 - Jul 8
| |||
Form 4
| -3.35% | -95.00K |
$5.42 | -$514,900.00 | 2.74M |
Jul 1
| |||
Form 4
| -2.44% | -71.00K |
$5.31 | -$376,797.00 | 2.83M |
Jun 29
| |||
Form 4
| -0.92% | -54.00K |
$5.36 | -$287,009.90 | 5.82M |
Jun 28
| |||
Form 4
| -0.20% | -6.00K |
$5.52 | -$33,114.00 | 2.96M |
Jun 18
| |||
Form 4
| -3.39% | -104.00K |
$5.40 | -$561,600.00 | 2.97M |
Jun 16
| |||
Form 4
| -1.64% | -144.50K |
$6.00 | -$867,000.00 | 8.67M |
Jan 20 - Jan 21
| |||
Form 4
| -2.87% | -95.00K |
$6.05 | -$574,750.00 | 3.21M |
Jan 14
| |||
Form 4
| -0.72% | -24.00K |
$6.30 | -$151,200.00 | 3.31M |
Jan 9
| |||
Form 4
| -26.26% | -1.19M |
$6.20 | -$7,359,400.00 | 3.33M |
Dec 31
| |||
Form 4
| -39.17% | -2.91M |
$7.69 | -$22,385,590.00 | 4.52M |
Oct 17
| |||
| No matching records found | |||||||||
IMMUNE DESIGN CORP. No price found
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -15.77% | -902.00K |
$1.83 | -$1,653,907.20 | 4.82M |
Dec 4
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Oncothyreon Inc. No price found
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 23
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| -41.40% | -4.00M |
—
|
—
| 5.66M |
Feb 5
| |||
Form 4
| +4.08% | 378.44K |
$1.82 | $688,678.86 | 9.66M |
Dec 15 - Dec 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| -7.41% | -554.24K |
$3.24 | -$1,795,731.12 | 6.92M |
Jul 16
| |||
Form 4
| +1.76% | 129K |
$1.78 | $229,620.00 | 7.48M |
Nov 1
| |||
Form 4
| +3.64% | 258.36K |
$1.65 | $426,166.47 | 7.35M |
Aug 8
| |||
Form 4
| +5.01% | 338.09K |
$1.76 | $589,602.29 | 7.09M |
Jul 31 - Aug 1
| |||
Form 4
| +1.09% | 214.47K |
$1.79 | $387,225.99 | 19.95M |
Jun 5 - Jun 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||